Bright Minds Biosciences
DRUG
9 hedge funds and large institutions have $2.93M invested in Bright Minds Biosciences in 2021 Q4 according to their latest regulatory filings, with 9 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
1.54% more ownership
Funds ownership: 0% → 1.54% (+1.5%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$2.94M |
| 2 |
IC
Ikarian Capital
Dallas,
Texas
|
+$445K |
| 3 |
AI
AdvisorShares Investments
Bethesda,
Maryland
|
+$427K |
| 4 |
QFA
Quattro Financial Advisors
The Woodlands,
Texas
|
+$94.1K |
| 5 |
CCA
Checchi Capital Advisers
Beverly Hills,
California
|
+$62.9K |
Top Sellers
DRUG Hedge Fund Activity: Q4 2021 in Review
9 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in Bright Minds Biosciences (DRUG) for Q4 2021, worth a combined $2.93M.
Buyers outnumbered sellers: 9 funds opened new DRUG positions and 0 closed out — a net gain of 9 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was OrbiMed, opening a new position worth an estimated $2.94M.
- 9 institutional investors held Bright Minds Biosciences (DRUG) as of Q4 2021, up from 0 in Q3 2021.
- Funds reported $2.93M of Bright Minds Biosciences stock for Q4 2021.
- 9 funds opened new Bright Minds Biosciences positions in Q4 2021 and 0 closed out, a net change of +9 holders.
- The largest Bright Minds Biosciences buyer in Q4 2021 was OrbiMed, an estimated $2.94M added.
Based on aggregated 13F filings for Q4 2021.